Patients with underlying chronic liver disease (CLD) may develop drug-induced liver injury during clinical care or in clinical trials, and it is associated with poor outcomes. This lecture discusses medications and herbal agents that are commonly implicated in DILI, risk factors, strategies for  monitoring patients in clinical trials, guidelines for adjudicating suspected DILI events and outcomes associated with DILI in CLD.Mark I.

This program aims to help attendees understand how to best approach the patient referred for evaluation of an incidentally found liver mass, be better informed on how to conduct office-based noninvasive assessment of liver fibrosis in the patient with elevated liver tests, increase their understanding of the management of alcoholic liver disease in 2018 and have the knowledge to provide care in the post-liver transplant patient in the community setting.K. Rajender Reddy Marcelo Kugelmas Craig J. McClain Kirti Shetty

This program reviews the most recent advances in the clinical management of patients with cirrhosis. Topics of discussion include the use of beta blockers, anticoagulants and albumin for managing different complications of cirrhosis. Additionally, the most updated recommendations regarding  screening issues for patients with cirrhosis will be reviewed.Michael B. Fallon Michael B. Fallon, MD, FAASLD is Professor and Chair of the Department of Medicine at the University of Arizona College of Medicine – Phoenix (UACOMP).

This session will describe the biological and social determinants of health that contribute to ethnic and racial disparities in health and health care; identify the racial and ethnic disparities that have been documented in patients with primary HCC and liver transplantation; and list strategies to prevent viral hepatitis, reduce deaths and decrease health disparities due to HBV and HCV in the U.S.Stephen Thomas Fasiha Kanwal Fasiha Kanwal, MD, MSHS, AGAF, FAASLD is a professor of medicine and chief of Gastroenterology and Hepatology at Baylor College of Medicine.

Kim Loh, Shanna Tam, Lisa Murray‐Segal, Kevin Huynh, Peter J. Meikle, John W. Scott, Bryce van Denderen, Zhiping Chen, Rohan Steel, Nicholas D. LeBlond, Leah A. Burkovsky, Conor O’Dwyer, Julia R.C. Nunes, Gregory R. Steinberg, Morgan D. Fullerton, Sandra Galic, Bruce E. Kemp – 12 November 2018 – Adenosine monophosphate–activated protein kinase (AMPK) regulates multiple signaling pathways involved in glucose and lipid metabolism in response to changes in hormonal and nutrient status.

Chronic HBV (CHB) infection follows a dynamic course with multiple phases of disease with various durations.  ALT flares during CHB can be challenging for clinicians to manage.  In some settings ALT flares herald a transition from active to inactive disease and thus are considered to be beneficial. In other scenarios, they may indicate aggressive inflammatory liver disease than can lead to progressive liver injury or even fulminant hepatic failure.

This program has been designed to improve the diagnosis, pharmacologic treatment and management of patients with chronic liver disease. The current data is highlighted to support effective and efficient patient-centered care. Attendees will gain the ability to utilize medical knowledge and research to provide quality, evidence-based care and to enhance interdisciplinary collaboration to improve health outcomes.Lisa M. Richards Lisa Richards, FNP-BC, MSN, AF-AASLD is a board certified Family Nurse Practitioner with the University of California San Diego Health System.

This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.Jessica Zucman-Rossi Augusto Villanueva Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York).

This program will provide practicing clinicians with an update on recent changes in the epidemiology of alcoholic liver disease, advances in understanding of its pathophysiology and the impact of social policies on alcohol use disorders. The program will then present advances in the treatment of alcohol abuse and alcoholic liver disease, including novel models of multidisciplinary care for these patients.Jessica L. Mellinger Ian Gilmore Robert Weinrieb Vijay Shah

This activity will provide updates and practical guidance for care providers dealing with 3 common and or difficult to manage conditions. The knowledge will improve practitioner's performance as care providers and will improve patient outcomes.Cynthia Levy Cynthia Levy, MD, FAASLD is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases. Dr. Levy received her M.D.